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Abstract: The large amount of iodine-131 (131I) activity excreted by the patient via perspiration, saliva, breath 
and urine during hospitalization may develop radiation contamination hazard. The aim of this study was to 
measure the level of contamination activity from skin and room surfaces throughout radioiodine ablation 
patient’s hospitalization and to determine the correlation between the administrated dose and level of 
contamination activity from skin and room surfaces. The removable activity was measured from nine patients 
treated with radioactive 131I with doses ranged from 3.0 to 5.5 GBq (80 – 200 mCi). The measurement was made 
at patient’s skin and room surfaces in the three-time interval of 4, 10 and 24 hours. The results showed that the 
removable activity for skin and room surfaces exceeds the regulation level for most of the time post 131I 
administration throughout patient’s hospitalizations. There was no significant correlation between levels of 
surface contamination and treatment dose received by the patient. The radiation safety precautions must be 
considered in order to minimize radiation exposure to the family, personnel and community either during 
hospitalization or after discharge. 
Keywords: Iodine-131 (131I), Radioiodine ablation, Radiation contamination, Radiation exposure, Surface 
contamination. 
 
I. INTRODUCTION  
 Radioiodine ablation is a treatment of choice for thyroid cancer patient following total thyroidectomy 
in which radioactive source is used. The goal of ablation is to destroy these remnants in a belief that such 
therapy will be followed by a reduction in recurrences and mortality from the carcinoma [1]. High dose 
radioactive Iodine-131 (131I) is administered in a large amount of activities between 2.75 to 7.4 GBq (75 – 200 
mCi) [2]. 87% of patients with residual thyroid bed tissue can achieve total ablation with 3700-7400 MBq (100-
200 mCi) and no significant increment was observed by giving higher doses [3]. The administration of 131I is 
normally by the oral route, intravenous injection, or installation of colloidal suspensions into closed body 
cavities [4]. 
131I emits both negative beta particles with maximum energy approximately 807 keV which delivers the 
major radiation dose to the remnant thyroid tissue and a prominent 364-keV gamma photon which poses a 
potential radiation hazard to others outside the patient’s room [5]. The patients become a risk of radiation 
exposure and potential radiation hazards to the other individuals after radioiodine therapy administration. Most 
patients who receive high dose of 131I therapy are isolated in a private room from two to three days to allow the 
radiation exposure rates drop to the accepted levels for radiation protection purposes [6, 7].  The isolation 
procedures are commanded to minimize the transfer of contamination to the hospital personnel or visitors. Upon 
released of the patient, it is required to properly instruct them in order to minimize the radiation contamination 
and exposure to the person living with or coming in contact with the patient [8].  
Radioiodine is secreted in body fluids such as sweat and saliva and excreted into urine and faeces [9]. 
The amount of residual thyroid tissue in thyroid cancer patient determines the radioiodine retention and 
clearance rate. Patients undergoing second treatment will have less thyroid tissue compared to those undergoing 
initial treatment, thus they have higher clearance rate. In cancer patients, because of the lack of thyroid tissue, 
most of the administered activity will appear in the urine. The fraction is largely be determined by the amount of 
remnant and metastatic thyroid tissue. In most cases, 50-60% of the administered activity is excreted in the first 
24 hours, and around 85% over a stay of 4-5 days. This represents a significant potential for radioactive 
contamination [3].  
Due to the large amount of activity excreted by the patient during hospitalization, contamination hazard 
may arise from 131I via urine, saliva and perspiration and potential vomitus. The excretion would results in the 
possibility of contamination of the patient’s environment and of inadvertent ingestion by other persons [4]. 
Radioactive contamination is described as the contamination of any material, surface or environment or of any 
person, including both external skin contamination and internal contamination irrespective of the method of 
intake, by any radioactive material, nuclear material or prescribed substance [10]. The contamination risk to the 
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relatives of patients and community members through external rays and body fluids from patients in the 
treatment of radioactive iodine is an important issue that needs to be considered [11]. Precautions should be 
taken to limit the radiation exposure of the nuclear medicine physician, nursing personnel, the patient’s family, 
and members of the public with whom a treated patient may come in contact. These precautions vary among 
countries, but recommendations are usually based on measurement of 
131
I retention or instantaneous dose rates 
[9].  
There are very few reports regarding the 131I contamination during the radioiodine therapy for thyroid 
cancer patients. One of the study found that the removable activity from the skin and room surfaces exceeded 
acceptable levels of removable contamination for restricted areas during hospitalization and at a time of 
discharge [8]. The European Union (EU) states that treatment of thyroid cancer using radioiodine 131I should 
only be performed on inpatients and the patient must be hospitalized for at least 48 hours [4]. The United State 
Nuclear Regulatory Commission (NRC) guide 8.39 describes several options for patient release after 
radioiodine therapy: the administered activity of the patient less than 1.2 GBq, dose rate less than 18.1x10-7 Ckg-
1/hr or 7 mR/h at 1 meter [12]. The purpose of this study was to measure the level of contamination activity 
released by patients treated with radioiodine therapy during hospitalization and to determine the correlation 
between the administrated dose and level of contamination activity from skin and room surfaces. 
 
II. MATERIALS AND METHODS 
2.1 Patients and Treatment 
 Nine patients received 131I ablation following thyroidectomy for follicular and papillary thyroid cancer 
has been chosen as subjects for this study. The patient population consisted of 3 males and 6 females. The age 
ranged from 16 to 73 years old with a mean age of 50.56 years. The number of sample size is small due to lack 
of thyroid ablation cases in this hospital. Based on the previous study conducted in Wisconsin United State, only 
eight patients with thyroid cancer treated with activities ranging from 3.7 to 14.8 GBq [8]. Patients were 
administered a therapeutic amount of 131I - labelled sodium iodide orally which in activity from 3.0 to 5.5 GBq 
(80 to 150 mCi). Patients were hospitalized and isolated for about two days until the administered activity was 
no greater than 1.2 GBq [11]. Each patient was informed about the procedure and gave their consent.  
 The removable surface contamination levels were measured from the room surfaces, the toilet bowl 
surface and the skin surface. The samples of removable contamination were obtained for three times during 
patient’s hospitalization, which were at 4, 10 and 24 hours. Alcohol swabs were used to get the samples from 
patient’s skins and room surfaces. All wipe samples were taken from an area about 2cm x 5cm. The skin wipe 
samples were taken from the forehead, neck, chest, forearm and palm. While wipe samples for room surfaces 
contamination were obtained from tray stand, faucet, door handle and surface of toilet bowl. All samples were 
measured using thyroid uptake probe that was calibrated by using residual syringe with 1.45 mCi of 131I. The 
energy spectrum of the 364keV peak of 131I selected at 15% of the windows. The sensitivity test was performed 
to test the constancy of instrument and setting. The calibration result is 45.9 kcps/μCi. Known activity of 131I 
source was counted to convert counts to units of Becquerel per centimetre square. The background was counted 
to ensure the instrument stability.  
 
2.2 Statistical Analysis 
 Data were analyzed to find the correlation between 
131
I treatment dose and the removable activity 
detected at 4, 10 and 24 hours after oral administration. Nonparametric or distribution-free statistical test was 
chosen and correlation between the continuous variables was analyzed with the Spearman’s rank order 
correlation. All data analysis was conducted using Statistical Package for Social Sciences, Predictive Analysis 
Software version 18 (SPSS PASW 18). 
 
III. RESULTS 
 Fig. 1 – 5 showed the results of removable 131I contamination measurements from skin surfaces post 
radioiodine administration at different time interval 4, 10 and 24 hours. The removable surface activity from 
room surfaces at 4, 10 and 24 hours has been demonstrated in Fig. 6. These graphs displayed are subdivided 
according to the dose received by the thyroid cancer patients. There were six patients who received 3.7 GBq, 
and one patient for each 3.0 GBq, 4.4 GBq and 5.5 GBq. Measurement of the activities of all skin wipe samples 
range from less than 20 Bq/cm2 to over 400 Bq/cm2. Some of the surface showed no removable activity, while 
most of them exceed the limit as stated in US NRC Regulatory guide 8.23 [12]. Wipe samples taken from the 
five skin surfaces and four room surfaces showed a different time activity pattern. The highest removable 
contamination for skin surfaces detected 4 hours post administration at chest region which is 427 Bq/cm2 for 
patient treated with 3.0 GBq of 131I (Fig. 3). The mean activity for other skin surfaces was eventually equal for 
all cases. 
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 In Fig. 6, the removable activity from room surfaces ranged from less than 30 Bq/cm2 to over 7.3 
kBq/cm2. Removable activity of room surfaces showed the greatest contamination which at toilet bowl surfaces 
for the same subject who received 3.0 GBq of 131I. According to the graphs, the highly potential contaminated 
room surfaces are the faucet and toilet bowl surfaces. This may result from frequent visit to the toilet for all 
subjects. The removable activity was high for all wipe samples at 4 hours post 
131
I administration with exclusion 
for subject treated with 3.0 GBq. Upon 24 hours post therapy, the results showed that the removable activity for 
some subjects was decreasing while for some of them the activity was increasing.  Subject treated with 3.0 GBq 
shows reduction in contamination activity for most skin and room surfaces except for toilet bowl surface.  
 The removable contamination for all cases either for skin or room surfaces were inconsistent. Generally 
it is assumed that the removable contamination is proportional to the administered dose received by the patient. 
But the study showed there was no significant correlation between radioiodine contamination and administrated 
dose.  
 
 
Figure 1. The removable activity of 131I from forehead at different time interval for different administrated 
doses. 
 
 
Figure 2. The removable activity of 131I from neck at different time interval for different administrated doses. 
 
 
Figure 3. The removable activity of 131I from chest at different time interval for different administrated doses. 
 
 
Figure 4. The removable activity of 131I from forearm at different time interval for different administrated doses. 
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Figure 5. The removable activity of 131I from palm at different time interval for different administrated doses. 
 
 
Figure 6. The removable activity of 131I from room surfaces; tray stand, door handle, faucet and toilet bowl at 
different time interval for different administrated doses. 
 
 Table 1 demonstrated correlation between administered dose and removable surface activity per 
centimetre square at different time interval 4, 10 and 24 hours post 131I administration for skin surfaces. The 
results showed greater removable activity variability at different time interval 4, 10 and 24 hours post 131I 
administration (Table 1 and Table 2). At 4 hour post administration only forehead, neck and forearm showed no 
significant positive correlation between treatment dose and removable activity for the skin surface. Neck, 
forearm and palm showed no significant negative correlation between treatment dose and removable activity at 
10 hour post ablation. The forehead surface however showed no significant relationship between treatment dose 
and removable activity (r = 0.00, p = 1.000). At 24 hour post administration the entire skin surface involved also 
showed no significant positive correlation between treatment dose and removable activity except palm. 
 
Table 1: Correlation between 131I treatment dose and removable activity at 4, 10 and 24 hours post 131I 
administration for different skin surfaces. 
Skin Surfaces Time Interval 
(hours) 
Correlation Coefficient (r) p-value 
Forehead 
4 0.16 0.679 
10 0.00 1.000 
24 0.34 0.411 
Neck 
4 0.59 0.095 
10 -0.16 0.683 
24 0.48 0.188 
Chest 
4 -0.06 0.888 
10 0.21 0.584 
24 0.47 0.20 
Forearm 
4 0.42 0.257 
10 -0.16 0.683 
24 0.61 0.084 
Palm 
4 -0.34 0.374 
10 -0.23 0.547 
24 0.70 0.037 
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 Table 2 represented the correlation between administered dose and removable surface activity per 
centimetre square at different time interval; 4, 10 and hours post 131I administration for room surfaces. 
According to table 2, entire room surfaces involved in this study showed negative correlation but not significant 
between treatment dose and removable activity at 4 hour post ablation. The situation was similar at 10 hour post 
ablation except for toilet bowl surface which showing significantly negative correlation. At 24 hours post 
ablation only toilet bowl surface showed no significant negative correlation compared to other surfaces (r = -
0.34, p-value = 0.364). 
 
Table 2: Correlation between 131I treatment dose and removable activity at 4, 10 and 24 hours post 131I 
administration for different room surfaces. 
Room 
Surfaces 
Time Interval (hours) Correlation Coefficient (r) p-value 
Tray stand 
4 -0.07 0.859 
10 -0.20 0.615 
24 0.66 0.055 
Door 
handle 
4 -0.21 0.597 
10 -0.42 0.257 
24 0.54 0.132 
Faucet 
4 -0.46 0.210 
10 -0.20 0.615 
24 0.53 0.143 
Toilet bowl 
4 -0.20 0.599 
10 -0.70 0.035 
24 -0.34 0.364 
  
Based on Table 1 and Table 2, no significant correlation was found between the dose administered and 
removable activity for most of skin and room surfaces. But however, removable activity for palm at 24 hours 
post ablation, showed significantly positive correlation with the treatment dose (r = 0.70, p-value = 0.037). 
There was also significantly good negative correlation between treatment dose and removable activity at 10 
hours post 131I administration for toilet bowl surface (r = -0.70, p-value = 0.035). 
 
IV. DISCUSSION 
Referring to US NRC Regulatory Guide 8.23 [13], the level of contamination in restricted area at 
which clean up is recommended is 2200 dpm/100cm2 or 0.36 Bq/cm2. In this study, the removable activity for 
skin and room surfaces exceeded the regulation level for most of the time post 131I administration throughout 
patient’s hospitalizations. The high contamination level probably indicates the amount of contact each surface 
has with the patient’s hands and saliva [8]. In this study, there was no significant correlation between the 
treatment doses and activity levels of contamination. The patient who received 80 mCi 131I may have high 
surface contamination compared to patient treated with 200 mCi. The contamination for the patients received 
same amount of treatment doses also not necessarily same. It may vary from patient to patient.   
The contamination from the radioiodine patient is not dependent on the amount of the radioactive 131I 
they had received, but it strongly depends on the patients behaviour, biologic processes and their compliance 
with the safety instruction given by the radiation safety officer and other medical staff. For bound radioiodine 
(fraction taken up by thyroid and other tissues) the biological half-life will vary from patient to patient, 
depending on the amount of thyroid tissue, their thyroidal hormonal status, and the presence of any metastatic 
deposits, and is very much longer compared to the physical half-life [3]. The total amount of radioactive iodine 
reduces to half of its original value at a rate depends on the state of disease which is between one day for total 
ablation of thyroid cancer tissue [11].  
The uptake of radioactive 131I in the thyroid cancer often depends on the condition of the thyroid, 
whether it has been removed or not, and it varies from patient to patient for the same amount of radionuclide. 
The biologic processes of the patients also affect the clearance of radionuclide. Patients received 131I therapy do 
not retain radioactivity for the physical half life of the radionuclide, but they eliminate 131I more quickly because 
of biologic elimination [14]. The available excretory pathways for radionuclide administered in therapy include 
urine, faeces, saliva, sweat, lachrymal fluid and breast milk. Each pathway has different safety issues and all can 
lead to contamination. The clearance rate from the patient’s body can vary greatly for different pathways. In 
addition, they vary within any one pathway not only between radiopharmaceuticals but also for the same 
radiopharmaceutical in different patients [4]. Other factors affecting the activity levels in thyroid cancer patients 
were the amount of remnants tissue, renal insufficiency and patients abiding the rules such as cleaning urine 
contamination, changing clothes frequently, taking shower often and being well hydrated [11].  
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Upon administration of the dose, the labelled compound was readily absorbed from the gastrointestinal 
tract and distributed in the extracellular fluid of the body, concentrating in remnant thyroid tissue, the stomach, 
and salivary glands, with a portion recirculated back to these tissues. For most patients, some 30%–75% of the 
administered dose can be expected to be excreted in the urine, perspiration and saliva within the first 24 hours 
after 
131
I administration [5, 15]. The removable 
131
I activities from skin surfaces and room surfaces during the 
first 4 hours for all treatment doses were reasonably high. At this time, the patients did not take shower and 
there were a contact between each surface with patients hand and saliva. After the 10 hours, it showed some 
reduction in amount of activity levels for skin and room surfaces. This may due to the patients have followed the 
instruction given by medical staff, such as to wash hand and shower frequently, drink fluid liberally to allow the 
131I excretion, and flushes the toilet bowl twice after used.   
Among the room surfaces, the toilet bowl surface showed the highest level of removable contamination 
for all time interval, 4, 10 and 24 hours. There were some patients who did not comply the instruction given by 
the staff. The patients also did not flush the toilet bowl more than once as instructed. The radiation still remains 
in the toilet bowl and did not get into the decay tank. The high contamination depends on the behaviour of the 
patients in using the bathroom and probably results from the wrong position practice during the urination [8]. 
The men were proposed to urinate by sitting on the toilet to prevent possible contamination around toilet area. It 
was important to instruct the patient carefully not to spill any urine and flush the toilet 2 or 3 times after use. 
Patients were advised to wash their hands thoroughly after any cleaning of contaminated items. The bathroom 
sink and tub must be rinsed after being used [15].  
 Most of the administered radioiodine not taken up by thyroid tissue is excreted by the urine in the 48 
hours or so following administration. However, some is excreted by perspiration, sweat and saliva. For this 
reason, patients are considered as a potential source of radiation contamination, especially during the first 48 
hours following administration. If nursing staff come into contact with the patient, bed linen, etc. while in the 
room, they must wear a gown and disposable gloves. Further, the patient's meals must be served on disposable 
plates and utensils [3]. Disposable items should be placed in a separate waste container for collection, 
measurement and appropriate disposal. Contaminated objects may need treatment to reduce radioactivity levels, 
or even storage for decay. 
 However, the removable 131I activities from skins and rooms surface were still high at the time of 
discharge. Therefore, the patients still have to follow the instruction given by staff even at home. Since the 
removable activity from the hands and other areas of the body were significantly high at time of discharge, the 
patients were advised to refrain from participating in cooking and food preparation for some time to avoid food 
contamination. In order to avoid contaminated disposable utensils going into normal trash, it was advisable and 
recommended to exclusively used personal plate, glassware and silverware which must be cleaned by the patient 
in a private bathroom sink and kept in the patient’s room for a daily use for 1 week. A failure in following the 
instructions by the patient resulted in contamination incident in some local community [15].  
 The activity levels of saliva and exhaled breath of the patients have positive correlations with treatment 
dose. So, it was necessary to instruct the patients to avoid from open mouth kissing and sharing personal with 
other family members. Extra precautions are necessary for patients with cold or flu symptoms because frequent 
sneezing and nose blowing can spread the radiation exposure to others [8]. In order to prevent contamination to 
the community, patients should be instructed to limit the time spent in public access the first few days and avoid 
places such as theatre, sport arenas or stadium where the option of getting a seat farther away from others may 
not always be possible [15].  
 The radiation safety precautions must be discussed properly with both patient and the family members 
to minimize radiation exposure to the family and community. With the proper education and clear instructions, 
the radiation exposure and contamination can be minimized [15]. The patients must be given clear instructions, 
including written instructions, on how to maintain doses to other individuals as low as reasonably achievable 
after they were released [12]. 
 
V. CONCLUSION  
 Radioiodine ablation is one of the most effective methods of treating the remnant thyroid tissue. High 
activity of 131I is used to ablate thyroid remnant or to treat metastasis disease in patient with thyroid cancer. 
After the 131I administration, the patient becomes a potential radiation hazard to other individuals. 
 The levels of removable 131I activity for thyroid cancer patients are reasonably high for skin and room 
surfaces during their hospitalization. Upon discharge, the removable 131I activity for wipe samples is still 
significantly high for all the patients for various treatment doses. The study has shown that no significant 
correlation between treatment dose and level of surface contamination. These findings emphasize the 
importance of awareness on radiation surface contamination among hospital personnel and patients. It is 
important to instruct the patient to follow the radiation safety precaution in order to minimize radiation exposure 
and contamination hazards to personnel, family and community. It is recommended that the association of these 
factors is investigated in future studies. 
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